189 related articles for article (PubMed ID: 36591509)
1. Identification of prognosis-related gene features in low-grade glioma based on ssGSEA.
He Y; Lin Z; Tan S
Front Oncol; 2022; 12():1056623. PubMed ID: 36591509
[TBL] [Abstract][Full Text] [Related]
2. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
3. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
4. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
PeerJ; 2024; 12():e16874. PubMed ID: 38406287
[TBL] [Abstract][Full Text] [Related]
5. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
6. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.
Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X
Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109
[TBL] [Abstract][Full Text] [Related]
7. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma.
Wen J; Zhao W; Shu X
Front Oncol; 2022; 12():1087762. PubMed ID: 36776374
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
9. Identification and Verification on Prognostic Index of Lower-Grade Glioma Immune-Related LncRNAs.
Wen J; Wang Y; Luo L; Peng L; Chen C; Guo J; Ge Y; Li W; Jin X
Front Oncol; 2020; 10():578809. PubMed ID: 33330055
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Model and Nomogram Construction and Validation With an Autophagy-Related Gene Signature in Low-Grade Gliomas.
Li X; Huang Z; Zhu L; Yu F; Feng M; Gu A; Jiang J; Wang G; Huang D
Front Genet; 2022; 13():905751. PubMed ID: 35923699
[No Abstract] [Full Text] [Related]
11. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
12. Foreboding lncRNA markers of low-grade gliomas dependent on metabolism.
Lu Z; Feng Y
Medicine (Baltimore); 2022 Nov; 101(44):e31302. PubMed ID: 36343057
[TBL] [Abstract][Full Text] [Related]
13. Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.
Ye L; Xu Y; Hu P; Wang L; Yang J; Yuan F; Wang Y; Zhang C; Tian D; Chen Q
Front Mol Neurosci; 2021; 14():720899. PubMed ID: 34776862
[No Abstract] [Full Text] [Related]
14. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Guo F; Hong J
Front Genet; 2020; 11():441. PubMed ID: 32431729
[TBL] [Abstract][Full Text] [Related]
15. New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis.
Chen D; Yao J; Hu B; Kuang L; Xu B; Liu H; Dou C; Wang G; Guo M
Chin Neurosurg J; 2022 May; 8(1):12. PubMed ID: 35585639
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
17. Comprehensive Analysis of Inflammatory Response-Related Genes, and Prognosis and Immune Infiltration in Patients With Low-Grade Glioma.
Han T; Zuo Z; Qu M; Zhou Y; Li Q; Wang H
Front Pharmacol; 2021; 12():748993. PubMed ID: 34712139
[No Abstract] [Full Text] [Related]
18. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
19. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a three-gene signature as a candidate prognostic biomarker for lower grade glioma.
Xiao K; Liu Q; Peng G; Su J; Qin CY; Wang XY
PeerJ; 2020; 8():e8312. PubMed ID: 31921517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]